Cynata Therapeutics (ASX:CYP) YoY EBITDA Growth : 18.75% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cynata Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 18.75%.

Cynata Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.04.

Cynata Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Cynata Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics YoY EBITDA Growth Chart

Cynata Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

YoY EBITDA Growth

Get a 7-Day Free Trial

-53.13

31.63

-41.79

-17.89

Cynata Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															-36.59	-39.29	14.29	-64.10	18.75

Cynata Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cynata Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

	YoY EBITDA Growth (A: Jun. 2023 )
=	(EBITDA per Share (A: Jun. 2023 )	-	EBITDA per Share (A: Jun. 2022 ))	/	\| EBITDA per Share (A: Jun. 2022 ) \|
=	(-0.112	-	-0.095)	/	\| -0.095 \|
=	-17.89 %

Cynata Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.039	-	-0.048)	/	\| -0.048 \|
=	18.75 %

Cynata Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

51S:Germany

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines